Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Marky1on Feb 09, 2021 3:50pm
283 Views
Post# 32516198

RE:Just Flying Around

RE:Just Flying AroundKept my promise...said that I'd be back only when the SP got over 5$...Just wanted to make a few points 1) Dr. Haut is just an amazing asset to ANTIBEs governing body..Kudos to Dan for bringing him on board. Basically, Dr. Haut was hired by AskBio last April...He put together a deal with Bayer to be acquired by Bayer for 4B$. ( 2B$USD upfront and another 2B$ to be paid later ) exactly 7 months after being taken on by BioAsk
If he follows the same pattern we hopefully should have a deal in Q3 2021....Bayer knows of him, probably comfotatalking with him..Dr.Haut knows the Bayer negotiation team, knows how to approach them...amazing find...

Then we have Dr. Stauffer...He worked for the FDA in the NSAIDS division...He knows the people to approach...knows what they are looking for, knows how to plan a solid P3 test....another amazing find

to Dan Legault...Thank you for all the hard work that you are doing on behalf of your 10,000 shareholders 
Kudos to you, Sir
JM
<< Previous
Bullboard Posts
Next >>